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Abstract
Objective: Metformin was assessed as an interventional medication for weight gain in children and adolescents
taking atypical antipsychotic agents.
Method: A 12-week open-label trial was conducted to evaluate metformin’s effectiveness and safety for weight
management. Eleven subjects, ages 10–18 years, participated in the study. Each subject received metformin orally
up to 2000 mg=day. Primary outcome measures included weight, body mass index (BMI), and waist circumference.
Secondary outcome measures included serum glucose, insulin, and fasting lipid profile. Changes in weight, BMI,
waist, and metabolic profile were obtained by using repeated measures of covariance.
Results: The mean reduction in weight, waist, BMI, serum glucose, and serum insulin was not statistically sig-
nificant. However, 5 out of 11 patients lost weight (mean,2.82 kg 7.25), and overall the sample did not continue
to gain weight. There was a significant decrease in triglyceride levels. Metformin was fairly well tolerated.
Conclusion: Preliminary data suggests that metformin may safely and effectively improve the triglyceride profile.
However, contrary to study hypotheses, weight, waist, and BMI reduction were not statistically significant. Future
double-blind studies with larger sample sizes and of longer duration are warranted to assess more fully the safety
and efficacy of this intervention.
Introduction
The use of atypical antipsychotic agents to treat pe-diatric mental illness, including bipolar disorder (BD),
schizophrenia, and pervasive developmental disorder (PDD)
has been increasing in prevalence (Findling et al. 2005). Their
use is often associated with weight gain and abnormalities in
metabolic profiles. For example, antipsychotics that produce
the greatest weight gain are associated with higher rates of
diabetes ( Jin et al. 2002).
Metformin, which is a biguanide oral hypoglycemic, de-
creases endogenous hepatic glucose production and intestinal
glucose absorption, while it increases insulin sensitivity
(Webb and Viner 2006). Metformin is approved for the
treatment of diabetes mellitus II in pediatric patients aged 10
and older ( Jones et al. 2002). It has been prescribed for patients
with noninsulin-dependent diabetes to control serum glucose
levels, and it has been reported to cause weight loss in several
groups of patients, including women with polycystic ovary
disease, obese men, and women with elevated lipid profiles
with and without noninsulin-dependent diabetes (Paolisso
et al. 1998; Kay et al. 2001; Bridger et al. 2006; Glueck et al.
2006; Srinivasan et al. 2006). In 2001, Freemark and associates
conducted a randomized, placebo-controlled, double-blind
trial in 29 obese adolescents. They concluded that metformin,
when given 500 mg twice daily, may be considered as an
adjunct to diet and exercise in teens at risk for diabetes mel-
litus II (Freemark and Bursey 2001). Morrison and colleagues
published a 12-week open-label study of metformin on 19
pediatric patients on psychotropic drugs who demonstrated
significant weight loss (15 of 19; mean, 2.93 3.13) on met-
formin (Morrison et al. 2002). Klein and colleagues, in their
randomized, double-blind, placebo-controlled trial of met-
formin in children and adolescents taking atypical antipsy-
chotics, found arrested weight gain, as well as improved
insulin resistance (Klein et al. 2006). Whereas Baptista and
associates found that metformin did not prevent olanzapine-
induced weight gain in a group of adult patients with
schizophrenia (Baptista et al. 2006), Wu and colleagues pub-
lished two studies indicating that metformin, administered to
a group of adult patients with schizophrenia on antipsy-
chotics, including olanzapine, was effective in attenuating
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weight gain and improving insulin sensitivity (Wu et al.
2008a; Wu et al. 2008b).
This study is an open-label, 12-week trial of metformin in
the treatment of weight gain and metabolic profiles in pedi-
atric patients who had gained weight on atypical antipsy-
chotics. We hypothesized that metformin would manage
weight gain, leading to weight loss, and improve metabolic
profile as conforming to the studies preceding this one.
Method
The Cambridge Health Alliance Institutional Review Board
approved the protocol. Written informed consent was ob-
tained from the child’s legal guardian and assent was ob-
tained from the child prior to participating in the study.
Patients were recruited from Cambridge Health Alliance in
Cambridge, Massachusetts. Patients with a diagnosis of BD,
schizophrenia spectrum disorder, and PDD, who were taking
risperidone, aripiprazole, or clozapine and had experienced
weight gain of more than 10% above baseline, were included
in the study. Subjects were excluded from participation if
they met criteria for an eating disorder, substance abuse=
dependence, significant medical or neurological illness, in-
telligence quotient (IQ) <70, inability to tolerate blood draws,
allergy to metformin, pregnancy, recent (in the past 3 months)
history of suicidality, clinically unstable on their current
medication regimen, and patients on their current antipsy-
chotic medication regimen for under 1 month.
Subjects were given metformin starting at 500 mg orally=
day, which was titrated up by 500 mg=week as tolerated
without side effects up to a target dose of 2000 mg per os=day.
Determination of past weight gain was based on clinical re-
cords and the patient’s weight upon enrollment into the
study. Patients were seen over a 12-week period with weekly
visits to monitor psychiatric symptoms, weight changes, side
effects, and metabolic profiles. Patients were instructed not to
change their baseline diet or activity level during the study.
Clinical measures and safety monitoring questionnaires were
conducted at all visits. The Brief Psychiatric Rating Scale
(BPRS) (Ventura et al. 2000) and Monitoring of Side Effects
System (MOSES) (Washington State, 2003) were used. La-
boratory tests for metabolic profile and liver function were
conducted at weeks 0, 4, 8, and 12. Fasting glucose was
measured every other week. Menarchal girls took a urine
pregnancy test prior to initiating the study medication.
Table 1. Demographics
Mean age 14 (SD 2.6)
Gender
Male 64%
Female 36%
Race
Caucasian 46%
African-American 18%
Hispanic 18%
Other=mixed 18%
Psychiatric diagnosis
Bipolar disorder 73%
Schizophrenia spectrum 9%
Ppervasive developmental disorder 18%
Abbreviations: SD, standard deviation.
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Descriptive statistics were obtained for all variables. A total
of 46% of subjects completed all 12 weeks of the medication
trial (2006–2007 rolling admission, n¼ 24). In addition to
metformin, 60% of subjects were being treated with risper-
idone, 30% were being treated with aripiprazole, and 10%
were being treated with clozapine.
The study’s primary outcome measures were change in
weight, body mass index (BMI), and waist circumference at 12
weeks of metformin treatment. Secondary outcome measures
included serum glucose, insulin, low-density lipoproteins
(LDL), high-density lipoproteins (HDL), cholesterol, and tri-
glycerides levels.
To evaluate the time course of improvement while being
treated with metformin, a linear mixed-model analysis was
fitted on the change in visit scores from baseline to comple-
tion, with sex, diagnosis, week, and age in the model. Ex-
ploratory analyses also included race in the model, but results
only showed a trend toward significance for insulin and
cholesterol; thus, race was only included in further analyses
with insulin and cholesterol. A Toeplitz covariance structure
was fit to the within-patient repeated measures using the
Kenward–Roger method (Kenward and Roger 1997) to esti-
mate degrees of freedom. Patients were analyzed on an intent-
to-treat (ITT) basis for all analyses. Patients with a baseline
and at least one post-baseline measurement were included in
the analyses. All p values were based on two-tailed tests with
significance level of 0.05.
Results
Table 1 lists the demographic characteristics of the patients
enrolled in the study. Duration of participation (weeks) in the
study was a significant predictor of triglyceride levels and
showed a trend toward significance to cholesterol and LDL
(F¼ 4.48, df¼ 3, 9.05; p< 0.05; F¼ 3.10, df¼ 3, 10.12; p< 0.10;
F¼ 3.18, df¼ 3, 7.75; p< 0.10). The longer the patient was in
the study, the lower the triglyceride levels. However, duration
in weeks did not significantly predict a change in weight,
waist circumference, BMI, serum insulin, serum glucose, and
HDL levels. Diagnosis significantly predicted glucose and
insulin ( p< 0.05) and showed a trend toward significance for
BMI, LDL, and triglycerides ( p< 0.10). In general, patients
with bipolar disorder (BD) showed higher glucose levels and
greater BMI than patients with schizophrenia, who showed
higher levels than patients with PDD, whereas the opposite
pattern was true for insulin levels. Subjects with BD showed
higher levels of LDL than subjects with schizophrenia and
PDD, who showed similar levels of LDL. Subjects with PDD
showed the highest levels of triglycerides, followed by BD,
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Table 4. Side Effects Profile
Symptom Percentage
Decreased appetite 30.0
Irritability 27.8
Constipation 22.5
Decreased attention 19.4
Drowsiness 19.4
Anxiety 16.7
Abnormal taste 15.0
Musculoskeletal pain 15.0
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and then schizophrenia. Age also predicted weight and waist
measurements ( p< 0.05, p< 0.01), and a trend toward sig-
nificance for BMI and triglycerides ( p< 0.10). Younger sub-
jects showed lower triglycerides levels, and there was an
increase in level with age. Both weight and waist circumfer-
ence increased with age. Sex showed statistical significance
with regard to glucose ( p< 0.05), and race showed a trend
toward significance for cholesterol ( p< 0.10). Males showed
slightly higher levels of glucose than females, whereas Cau-
casians showed higher levels of cholesterol, followed by other,
African-American, and Hispanic subjects.
A further increase in weight experienced from the atypical
antipsychotics during the course of the trial was arrested in all
patients. Five of 11 patients lost weight. Mean changes in
weight, waist, and BMI by length of follow up and overall, as
well as the mean serum glucose, insulin, LDL, HDL, choles-
terol, and triglycerides levels are summarized in Tables 2
and 3. The most common side effects reported by subjects are
listed in Table 4. Six subjects dropped out of the study prior
to completion due to a variety of reasons, including inabil-
ity to attend study visits, aggression, stomach aches, inability
to tolerate blood draws, and medication change.
Despite lack of significance, Figs. 1 and 2 show the de-
creases in weight and waist measurements from baseline to
end point. In addition, effect size is at least moderate, indi-
cating that there was a notable change in waist.
Discussion
In this preliminary evaluation of metformin as a treatment
for weight gain associated with atypical antipsychotics, a
further increase in weight experienced from these medications
was attenuated in all patients. In addition, 5 of 11 patients lost
weight. There was also a moderate effect size indicating a
decrease in waist circumference over time. However, met-
formin did not improve insulin sensitivity and showed a
trend toward increasing both LDL and cholesterol. Trigly-
ceride levels improved. In this sample of 11 patients, met-
formin was generally well tolerated.
This study has several limitations. First, it was an open-
label study and hence is subject to the placebo effect. How-
ever, the pattern of continued weight loss suggests that the
weight loss was not entirely due to the placebo effect. Second,
only a small number of patients was enrolled in this study, so
comparisons of weight loss between the various atypicals
were not possible. Similarly, the effect of different doses of
metformin was not evaluated. The effect of different psychi-
atric diagnoses on metformin response was not addressed in
this study. Third, although the patients were instructed not to
change energy intake or physical activity, some may have due
to increased motivation to lose weight. We did not obtain
hard data on dietary intake and=or physical activity, which
may themselves have become an intervention. Such informa-
tion would be essential in future studies. Fourth, the study may
not have been long enough to capture the full effect of met-
formin. Long-term follow-up studies are necessary to deter-
mine if further weight loss would occur over time and if, for
those who lost weight, weight loss is sustained.
In conclusion, metformin holds promise as a treatment for
weight gain in pediatric patients taking atypical antipsychotic
medications. Further studies, including randomized, con-
trolled trials and longer follow-up periods with larger sample
sizes, are warranted to determine the safety and efficacy of
this agent in these patients.
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FIG. 2. Change in weight from baseline to week 12. Dot/
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week 12. Dot/lines show means. P¼nonsignificant; Cohen’s
d¼ 0.58; effect size r¼ 0.28.
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